691 related articles for article (PubMed ID: 32865374)
1. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
[TBL] [Abstract][Full Text] [Related]
2. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
[TBL] [Abstract][Full Text] [Related]
3. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial.
Akao M; Yamashita T; Fukuzawa M; Hayashi T; Okumura K
J Am Heart Assoc; 2024 Feb; 13(3):e031506. PubMed ID: 38240204
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP; Ruff CT; Braunwald E; Murphy SA; Wiviott SD; Halperin JL; Waldo AL; Ezekowitz MD; Weitz JI; Špinar J; Ruzyllo W; Ruda M; Koretsune Y; Betcher J; Shi M; Grip LT; Patel SP; Patel I; Hanyok JJ; Mercuri M; Antman EM;
N Engl J Med; 2013 Nov; 369(22):2093-104. PubMed ID: 24251359
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
[TBL] [Abstract][Full Text] [Related]
8. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
9. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Minguet J; Sims HM; Smith KH; Bramlage P
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
[TBL] [Abstract][Full Text] [Related]
13. Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial.
Mikami T; Hirabayashi K; Okawa K; Betsuyaku T; Watanabe S; Imamura Y; Tanizawa K; Hayashi T; Akao M; Yamashita T; Okumura K
J Am Heart Assoc; 2022 Sep; 11(17):e024970. PubMed ID: 36056729
[TBL] [Abstract][Full Text] [Related]
14. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Blann AD; Skjøth F; Rasmussen LH; Larsen TB; Lip GY
Thromb Haemost; 2015 Aug; 114(2):403-9. PubMed ID: 26062437
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
Kirchhof P; Toennis T; Goette A; Camm AJ; Diener HC; Becher N; Bertaglia E; Blomstrom Lundqvist C; Borlich M; Brandes A; Cabanelas N; Calvert M; Chlouverakis G; Dan GA; de Groot JR; Dichtl W; Kravchuk B; Lubiński A; Marijon E; Merkely B; Mont L; Ozga AK; Rajappan K; Sarkozy A; Scherr D; Sznajder R; Velchev V; Wichterle D; Sehner S; Simantirakis E; Lip GYH; Vardas P; Schotten U; Zapf A;
N Engl J Med; 2023 Sep; 389(13):1167-1179. PubMed ID: 37622677
[TBL] [Abstract][Full Text] [Related]
17. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis.
Yamashita T; Koretsune Y; Yang Y; Chen SA; Chung N; Shimada YJ; Kimura T; Miyazaki K; Abe K; Mercuri M; Ruff CT; Giugliano RP
Circ J; 2016; 80(4):860-9. PubMed ID: 26888149
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
